ArticleTranslational andrology and urology2026
Long-term outcome of male urethral hemangioma: a two-center study.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of transurethral thulium laser cauterization in male patients with urethral hemangioma: a single-center retrospective case series.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Male urethral hemangioma is an exceedingly rare benign vascular tumor, research remains limited globally, and clinical research for it's long-term prognosis is scarce. This study aimed to investigate the procedural safety and long-term outcomes of male patients undergoing transurethral hemostasis/electrocautery for urethral hemangioma. Methods: Data from male patients with urethral hemangioma who had undergone transurethral hemostasis/electrocautery at two hospitals from July 2018 to December 2023 were retrospectively analyzed. Results: In total, twenty-nine patients with urethral hemangioma met our inclusion and exclusion criteria. Twenty-nine patients underwent surgery, of whom 16 (55.2%) underwent transurethral hemostasis, and 13 (44.8%) underwent transurethral electrocautery. All procedures were conducted successfully without intensive care unit (ICU) admission. The median procedural time was 20.0 [10.0-37.5] minutes. No intraoperative complications were detected. There was no report of unplanned re-catheterization or any documented postoperative complications, including urethral stricture, urinary incontinence, retrograde ejaculation, urethral bleeding, gross hematuria, or ejaculatory pain. After a median follow-up length of 50.0 months [interquartile range (IQR), 35.0-75.5 months], there were no cases of disease recurrence. Furthermore, no long-term complications were recorded during the surveillance period, including urinary incontinence, retrograde ejaculation, urethral bleeding, ejaculatory pain, urethral stricture, or hematuria. All patients remained symptom-free at their last follow-up evaluation. Conclusions: This study indicated that transurethral hemostasis/electrocautery offers high long-term stability and minor complications for male urethral hemangioma, representing a safe and effective treatment option. Clinical practice should enhance awareness of this condition, improve early diagnosis rates, and individualize surgical approach selection to optimize the outcomes and quality of life of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.